MicroVision Receives Nasdaq Global Market Listing

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
332
MicroVision Receives Nasdaq Global Market Listing Deficiency Notice

REDMOND, Wash., Dec. 31, 2018 (GLOBE NEWSWIRE) -- MicroVision, Inc. (Nasdaq: MVIS) announced today that it received a notice on December 28, 2018 from The Nasdaq Stock Market advising the company that for 30 consecutive business days preceding the date of the notice, the bid price of the company’s common stock had closed below the $1.00 per share minimum required for continued listing on The Nasdaq Global Market pursuant to Nasdaq’s listing requirements. In accordance with Nasdaq’s listing rules, the company has 180 calendar days, or until June 26, 2019, to regain compliance with this requirement. This notification is simply a notice of deficiency, not of imminent delisting, and has no current effect on the listing or trading of MicroVision’s common stock on The Nasdaq Global Market at this time.

During the 180-day compliance period, MicroVision can regain compliance if the bid price of its common stock closes at $1.00 or higher for a minimum of ten consecutive business days. If the company does not regain compliance by June 26, 2019, Nasdaq will notify the company that its securities are subject to delisting.

The company is monitoring the bid price for its common stock. The company continues to execute its business plan and will consider other actions that it may take in order to regain compliance with the listing requirements.

About MicroVision

MicroVision is the creator of PicoP® scanning technology, an ultra-miniature sensing and projection solution based on the laser beam scanning methodology pioneered by the company. MicroVision’s platform approach for this sensing and display solution means that its technology can be adapted to a wide array of applications and form factors. We combine our hardware, software, and algorithms to unlock value for our customers by providing them a differentiated advanced solution for a rapidly evolving, always-on world.

Extensive research has led MicroVision to become an independently recognized leader in the development of intellectual property. MicroVision’s IP portfolio has been recognized by the Patent Board as a top 50 IP portfolio among global industrial companies and has been included in the Ocean Tomo 300 Patent Index. The company is based in Redmond, Washington.

MicroVision and PicoP are trademarks of MicroVision, Inc. in the United States and other countries. All other trademarks are the properties of their respective owners.

Forward-looking Statements

Certain statements contained in this release, including those relating to MicroVision’s expectations, intentions or strategies, are forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those projected in our forward-looking statements include the following: the risk that MicroVision may not regain compliance with the continued listing standards of the Nasdaq Stock Market; capital market risks; our ability to raise additional capital when needed; market acceptance of our technologies and products, and for products incorporating our technologies; the failure of our commercial partners to perform as expected under our agreements; our ability to identify parties interested in paying any amounts or amounts we deem desirable for the purchase or license of intellectual property assets; our or our customers’ failure to perform under open purchase orders; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain additional contract awards and to develop partnership opportunities; the timing of commercial product launches and delays in product development; the ability to achieve key technical milestones in key products; dependence on third parties to develop, manufacture, sell and market our products; potential product liability claims; and other risk factors identified from time to time in the company’s SEC reports, including the company’s Annual Report on Form 10-K filed with the SEC. These factors are not intended to represent a complete list of the general or specific factors that may affect us. It should be recognized that other factors, including general economic factors and business strategies, may be significant, now or in the future, and the factors set forth in this release may affect us to a greater extent than indicated. Except as expressly required by federal securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changes in circumstances or any other reason. Additional Information Additional information relating to MicroVision can be found on EDGAR at www.sec.gov.

Contact:

Ted Moreau Darrow Associates, Inc. 608.298.7369 tmoreau@darrowir.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Blokees Unveils 90+ New Wonders at Shanghai Fest

Updated Category News Views 3

A Grand Stage for New Arrivals Picture this: In the bustling and glittering chaos that was the Wonder Festival Shanghai 2026, held from October 3 to 4, Blokees laid down a major marker. More than 500 products, an artillery of imagination and craftsmanship, were on deck across their key lines—Blokees Model Kits and BLOKEES WHEELS. With 90 brand-new creations making their...

Continue Reading
Monteverde Probes Four Key M&A Deals for Fairness

Updated Category News Views 6

Examining the Intricacies of Pending M&A The merger and acquisition landscape can be vicious, especially when the sharks—those pesky class action lawyers—start circling. And let me tell you, Monteverde & Associates PC is diving headfirst into the fray, launching inquiries into a handful of these deals. This isn't your first stroll down Wall Street if you’ve seen one...

Continue Reading
Black Culture Icon: Plastic-Covered Couch Takes Stage

Updated Category News Views 3

A Plastic-Laden Piece of History Makes Art Who'd have thought a plastic-covered couch would turn into a cultural artifact? This iconic staple in Black households has done just that, debuting at Brooklyn's CultureCon in a fresh guise. It's more than just an upcycled furniture piece; it's a living archive that encapsulates Black culture, joy, and resilience. The Heart...

Continue Reading
Class Action Alerts: M&A Under Scrutiny

Updated Category News Views 4

Unpacking Monteverde's M&A Investigations Hold your horses, folks! The M&A Class Action Firm is stirring the pot with its latest inquiries into some high-profile mergers. We're looking at Lisata Therapeutics, Flag Ship Acquisition Corporation, Baldwin Insurance Group, and ACV Auctions. So what's got Juan Monteverde's legal eagles swooping in on these deals? Well, are we...

Continue Reading
ARTBOX Brings Korean Lifestyle Magic to LA Pop-Up

Updated Category News Views 5

ARTBOX: From Seoul to La-La Land Here's what caught my eye. It's 2026, and Korean lifestyle retailer ARTBOX is making a splash in the U.S.—kicking things off with a pop-up in LA. Now, usually, I'd be skeptical about pop-ups, but you've got to admire the audacity and timing here. They've picked Melrose Avenue, a hotspot for all things trendy, to introduce their mix of...

Continue Reading
SiBionics and PharmaSens Unveil Diabetes Tech at EASD

Updated Category News Views 3

Shaking Up Diabetes Care: New Tech Unveiled Imagine a world where managing diabetes isn't a juggling act with multiple devices. That's precisely the future SiBionics and PharmaSens are pitching at the European Association for the Study of Diabetes (EASD) 2026 in Milan. Now, let me tell you, these guys aren't just playing around with ideas; they're aiming to radically...

Continue Reading
Lawsuit Highlights Inaction in School Bus Tragedy

Updated Category News Views 3

Seeking Justice Amid Heartbreak Tragedy rarely arrives whispered on the wind—more often, it's the train wreck some saw coming long before it hits. The tragic death of Jenna Menias, a 6-year-old from Frankfort, Illinois, falls squarely in this camp. The family's legal lions, Corboy & Demetrio, have slapped two school districts—District 210 and 157-C—with a wrongful...

Continue Reading
Monteverde's Equity Alert: Scrutinizing Recent M&A Deals

Updated Category News Views 6

Diving Into M&A Deals Under Monteverde's Lens Wall Street’s not just about suits and skyscrapers; it’s about the nitty-gritty of deals and whether those numbers add up in the investor's favor. So, when Monteverde & Associates PC throws its weight into scrutinizing mergers and acquisitions, you better believe it's worth a second look. See, they’re digging into four...

Continue Reading
Power Knot MEA Wins THE BIZZ 2026 for Excellence

Updated Category News Views 3

Setting the Pace in Waste Management If there's one thing that sticks in my craw, it's how businesses handle food waste. Power Knot Middle East (PKME) seems to have cracked the code by not just leading the charge in organic waste management but also bagging THE BIZZ 2026 award. They’re not just playing industry games; PKME's pulling the strings with real leadership and...

Continue Reading
Monster Energy Dominates Skateboard Podium at SLS Paris

Updated Category News Views 5

Monster Energy's Skateboard Triumph Hold the front page, because Monster Energy just pulled off a clean sweep in Paris. The company's team riders dominated the Men's Skateboard Street competition at the SLS Paris 2026, with the iconic Nyjah Huston snagging the top spot. It's a story filled with triumph, grit, and a dash of raw talent in a vibrant field of international...

Continue Reading

Top 5 Most Recently Viewed Articles

Strengthening Ties: Xi Jinping and Singaporean PM Wong Unite

Updated Category News Views 364

Strengthening Bilateral Relations for a Brighter Future In a significant meeting that highlights the growing ties between China and Singapore, President Xi Jinping recently welcomed Singaporean Prime Minister Lawrence Wong in Beijing. This engagement underscores the deepening friendship and collaboration between the two nations. During their discussions, President Xi...

Continue Reading
Revolutionizing 5G Processing with Ceva's Innovative Solutions

Updated Category News Views 283

Introduction to a New Era in 5G Technology As the world rapidly embraces the advancement of wireless communication, Ceva, Inc. (NASDAQ: CEVA) is spearheading a groundbreaking collaboration with Arm and SynaXG. This joint effort aims to significantly enhance energy efficiency in 5G New Radio (NR) processing, marking a major milestone for both terrestrial networks and Low...

Continue Reading
Alliance Trust PLC Announces Share Purchase Update

Updated Category News Views 113

Alliance Trust PLC Announces Share Purchase Alliance Trust PLC LEI: 213800SZZD4E2IOZ9W55 TRANSACTION IN OWN SHARES Recently, Alliance Trust PLC, known for its strategic investment approach, made a significant decision by acquiring 50,000 ordinary shares at a price of 1190.0p each. These shares will be held in Treasury, reflecting the company’s proactive strategy in...

Continue Reading
Lilabean Foundation and CBTN Unite for Pediatric Brain Cancer

Updated Category News Views 146

Advancing Pediatric Brain Cancer Research Together The Lilabean Foundation (LBF) is at the forefront of a significant movement to enhance pediatric brain cancer research through its innovative collaboration with the Children's Brain Tumor Network (CBTN). This partnership marks a transformative shift in how childhood brain tumors are treated and understood. Originally a...

Continue Reading
Eli Lilly's Breakthrough Drug EBGLYSS Offers Hope for Eczema

Updated Category News Views 351

A Promising Breakthrough for Eczema Sufferers Eli Lilly and Company (NYSE: LLY) has recently made headlines with the announcement of its innovative drug, EBGLYSS. This medication, functioning as an interleukin-13 (IL-13) inhibitor, has demonstrated substantial improvements in treating patients suffering from moderate-to-severe atopic dermatitis, particularly those who had...

Continue Reading